Brachytherapy trial enrolling new patients

March 1, 2005

Buford, GA—Patients are being enrolled into a clinical trial to evaluate the safety and feasibility of the TheraSight Ocular Brachytherapy System for treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration.

Buford, GA-Patients are being enrolled into a clinical trial to evaluate the safety and feasibility of the TheraSight Ocular Brachytherapy System for treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration.

The one-time brachytherapy treatment, sponsored by Theragenics Corp., compares three doses of radiation with a group of 30 patients at six clinical sites.

Eligible patients for the pilot study must have a lesion size ≤6 mm greatest linear dimension, submacular blood <75% of the lesion, subretinal fibrosis <25% of the lesion, study eye acuity 20/100 or poorer, and fellow eye acuity at least 1 line better than that of the study eye. For more information, contact Theragenics at 877/960-1234.